Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 6/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949469 | 0.92 | FSCN1 (0.42) | HDAC6HDAC1HDAC7FSCN1NTRK1 | |
| SCHEMBL2943245 | 0.90 | FSCN1 (0.42) | HDAC6HDAC10HDAC1HDAC7FSCN1 | |
| SCHEMBL2943251 | 0.89 | PPARG (0.43) | HDAC6HDAC10HDAC1FSCN1HDAC4 | |
| SCHEMBL4801984 | 0.89 | HDAC1 (0.37) | HDAC6HDAC1HDAC7FSCN1NTRK1 | |
| SCHEMBL2945087 | 0.87 | PPARG (0.42) | HDAC6HDAC10HDAC1HDAC7FSCN1 | |
| SCHEMBL1684175 | 0.86 | HDAC1 (0.38) | HDAC6HDAC10HDAC1HDAC7FSCN1 | |
| SCHEMBL2943310 | 0.86 | HDAC1 (0.44) | HDAC6HDAC10HDAC1HDAC7FSCN1 | |
| SCHEMBL2951370 | 0.86 | FSCN1 (0.42) | HDAC6HDAC10HDAC1HDAC7FSCN1 | |
| SCHEMBL4811553 | 0.85 | ICMT (0.40) | HDAC6HDAC1HDAC7FSCN1NTRK1 | |
| SCHEMBL2943244 | 0.85 | FSCN1 (0.40) | HDAC6HDAC1HDAC7FSCN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | PFIZER INC | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221154-A1 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE | TYMP, IMPDH1, POLB | HDAC6 570/4885HDAC10 104/4885HDAC1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.